Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One pill to replace three? diabetes combo drug tested

NCT ID NCT07333742

Knowledge-focused Sponsor: LG Chem Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a single pill containing three diabetes medicines (gemigliptin, dapagliflozin, and metformin) works the same in the body as taking them separately. Fifty healthy adults took either the combo pill or the separate drugs after a meal, and researchers measured drug levels in their blood. The goal was to see if the combo pill is a good alternative for simplifying diabetes treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gemigliptin, Dapagliflozin, Metformin
What this could lead to
If successful, this could allow people with type 2 diabetes to take one pill instead of multiple, simplifying their treatment.
What could go wrong
This is an early-phase study in healthy volunteers, not patients. It only checks how the drugs are absorbed, not if they work better or are safer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

50 people

The number who actually took part.

Started

Sep 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 19-50 years in healthy volunteers 2. 18.0 kg/m\^2 ≤ BMI ≤ 29.9 kg/m\^2, 50kg ≤weight ≤ 90kg 3. 60≤ FPG≤125 mg/dL 4. Subjects who voluntarily decides to participate in this clinical trial and agree in writing to ensure compliance with the clinical trial. Exclusion Criteria: 1. Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system. 2. Subjects with clinically significant abnormal findings during tests (or examinations) 3. Subjects with a history of hypersensitivity or clinically significant hypersensitivity reactions to test drugs or other drugs 4. Subjects judged ineligible by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fed conditions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fed conditions Healthy volunteer

Contacts and locations

Locations

  • Seoul National University Hospital

    Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.